Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that its Taiwanese partner, Orient Europharma, has concluded the Site Initiation Visit for the first Taiwanese clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy. The first center is called Shin Kong Wu Ho-Su Memorial Hospital and is located in Taipei, Taiwan.

24 Jun 2011

Scil Technology receives public research grant for novel rheumatoid arthritis treatments

Scil Technology GmbH, a biopharmaceutical company with core expertise in protein drug development, formulation and analytics, today announced that it has been awarded research funding by the German Federal Ministry of Education and Research (BMBF) under BMBF’s KMU-innovativ scheme. The EUR 0.9 million grant supports Scil Technology’s research program to explore the therapeutic potential of repellent proteins for the treatment of rheumatoid arthritis (RA).

23 Jun 2011

Silicone gel-filled breast implants: FDA releases updated data

The U.S. Food and Drug Administration released a report today updating the clinical and scientific information for silicone gel-filled breast implants, including preliminary safety data from studies conducted by the manufacturers as a condition of their November 2006 approval.

23 Jun 2011

Silicone-gel breast implant complications to be watched out for: FDA

The U.S. Food and Drug Administration (FDA) said Wednesday that women receiving silicone-gel breast implants have frequent complications like scarring or hardening breasts, and 20% or more of patients required implant removal within 10 years.

23 Jun 2011

Key trigger to rare but deadly neurodegenerative disease

Jeremy Smith, Governor's Chair for Molecular Biophysics at the University of Tennessee, Knoxville, has helped reveal a key trigger of Gerstmann-Str-ussler-Scheinker (GSS) syndrome, a rare but deadly neurodegenerative disease. The finding could have far-reaching implications for the treatment of other neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's.

23 Jun 2011

Disease-modifying antirheumatic drugs reduce risk of diabetes from RA, psoriasis

In a study that included nearly 14,000 patients with rheumatoid arthritis or psoriasis, the use of certain disease-modifying antirheumatic drugs was found to lower the risk of diabetes, according to a study in the June 22/29 issue of JAMA.

22 Jun 2011

CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

CEL-SCI Corporation announced today data from its Phase II clinical studies which showed that its lead drug Multikine was able to lower cholesterol in studies involving 120 head and neck cancer patients.

22 Jun 2011

Biotest, Abbott partner to develop and commercialize BT-061 for autoimmune diseases

Abbott and Biotest AG today announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis.

22 Jun 2011

Initiation of ALD518/BMS-945429 Phase 2b clinical trial in RA triggers milestone payment to Alder

Alder Biopharmaceuticals Inc. today announced it will receive a $15 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2b clinical trial in rheumatoid arthritis for ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6).

20 Jun 2011

NASDAQ halts Regeneron's common stock

Regeneron Pharmaceuticals, Inc. announced that NASDAQ has halted trading of the company's common stock.

17 Jun 2011

Positive results from etanercept pilot study against dermatomyositis

A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy.

17 Jun 2011

$Economic burden of fractures in Europe has been vastly underestimated: New report$

Economic burden of fractures in Europe has been vastly underestimated: New report

A new report launched today by the International Osteoporosis Foundation (IOF) in collaboration with the European Federation of Pharmaceutical Industry Associations (EFPIA) reveals that the burden of fractures in Europe has been vastly underestimated.

16 Jun 2011

Humira defect lawyers file suit against Abbott Laboratories in federal court

Humira defect lawyers filed a lawsuit against Abbott Laboratories in federal court today claiming Abbott's blockbuster drug, Humira, caused a fungal infection resulting in the near-death of a Tennessee man.

14 Jun 2011

Nose spray vaccine for type 1 diabetes could be a reality soon

Melbourne researchers are nearing the development of a vaccine for type 1 diabetes, after showing that a nasal spray can stop the body's immune system from attacking insulin-producing cells.

13 Jun 2011

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.

13 Jun 2011

Scientists identify potential target for reversing deadly blood infection sepsis

By digging a little deeper, researchers may have found a potential target for reversing the deadly blood infection sepsis.

13 Jun 2011

Hanwha, Merck partner to develop and commercialize HD203

Merck, known as MSD outside the United States and Canada, and Hanwha Chemical Corporation today announced that they have entered into an exclusive global agreement to develop and commercialize a candidate biosimilar form of Enbrel.

13 Jun 2011

NYU Langone webinar discusses advances in the treatment of RA

Steven Abramson, MD, professor of medicine and director of the rheumatology division at NYU Langone Medical Center, hosted a webinar with colleagues from the medical center for rheumatoid arthritis community bloggers - bringing together, bench, bedside and the blogosphere to discuss advances in the investigation, care, and treatment of RA.

13 Jun 2011

Rosa, Profil Institute partner to offer simulation technology for diabetes and obesity clinical trials

Profil Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, and Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, jointly announced today a strategic alliance to offer Profil Institute customers use of Rosa's modeling technology to simulate disease physiology, drug action, patient variability, and trial outcomes for their early phase clinical development programs.

8 Jun 2011

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA.

8 Jun 2011

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

Scil Technology receives public research grant for novel rheumatoid arthritis treatments

Silicone gel-filled breast implants: FDA releases updated data

Silicone-gel breast implant complications to be watched out for: FDA

Key trigger to rare but deadly neurodegenerative disease

Disease-modifying antirheumatic drugs reduce risk of diabetes from RA, psoriasis

CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

Biotest, Abbott partner to develop and commercialize BT-061 for autoimmune diseases

Initiation of ALD518/BMS-945429 Phase 2b clinical trial in RA triggers milestone payment to Alder

NASDAQ halts Regeneron's common stock

Positive results from etanercept pilot study against dermatomyositis

Economic burden of fractures in Europe has been vastly underestimated: New report

Humira defect lawyers file suit against Abbott Laboratories in federal court

Nose spray vaccine for type 1 diabetes could be a reality soon

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

Scientists identify potential target for reversing deadly blood infection sepsis

Hanwha, Merck partner to develop and commercialize HD203

NYU Langone webinar discusses advances in the treatment of RA

Rosa, Profil Institute partner to offer simulation technology for diabetes and obesity clinical trials

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in